Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center ...

Summary by Hastings Tribune
OCALA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data from the completed Phase 2 cisplatin-resistant advanced recurrent ovarian cancer clinical study utilizing Ampligen® (rintatolimod) was accepted in…

1 Articles

Hastings TribuneHastings Tribune
Center

AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center ...

OCALA, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that data from the completed Phase 2 cisplatin-resistant advanced recurrent ovarian cancer clinical study utilizing Ampligen® (rintatolimod) was accepted in…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Hastings Tribune broke the news in on Tuesday, November 4, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Ocala icon

Ocala

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal